Home › Research › Topics › blood-based
blood-based
706 studies tagged blood-based, dated 1989-01-01 to 2026-11-01. Bibliography: BibTeX (.bib) · RIS (.ris)
Newest in this topic
- Inflammatory biomarker candidates in dementia with Lewy bodies: diagnostic classification, clinical associations, and survival 2026-11-01
- Longitudinal plasma biomarkers and multimodal PET across APOE ε4 genotypes: a prospective cohort study 2026-11-01
- Concurrent cognitive, behavioral and systemic physiological features mark preclinical Alzheimer's disease 2026-10-30
Studies
706 studies carry this tag.
Date range
1989 to 2026
Top journals
- Alzheimer's & dementia : the journal of the Alzheimer's Association 126
- Journal of Alzheimer's disease : JAD 54
- Alzheimer's & dementia (Amsterdam, Netherlands) 46
- Alzheimer's research & therapy 36
- medRxiv 29
196 journals in all.
Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.
-
A combination of plasma Aβ42/Aβ40 and p-tau217 discriminated Aβ status with relatively high accuracy, whereas p-tau217 showed strongest associations with Aβ pathology in MCI but not in CU.
-
Mixed-effect models assessed rates of memory decline in relation to baseline plasma p-tau181, and whether plasma p-tau181 significantly predicted memory decline beyond widely available clinical and genetic data (age, sex, years of education, cardiovascular and metabolic conditions, and APOEε4 status).
-
Plasma biomarkers of amyloid, tau, and neurodegeneration (ATN) need to be characterized in cognitively unimpaired (CU) elderly individuals.
-
Twenty-seven iNPH, 27 AD, and 18 controls were included.
-
The same tube type should be used in research studies on blood biomarkers.
-
A blood-based screening tool can serve as a method for increasing access to state-of-the-art AD clinical research by bridging between community-based and clinic-based settings.
-
We found statistically significant batch differences for all biomarkers and ratios, except that neurofilament light was comparable between batches 1 and 2.
-
The PrecivityAD™ assays are precise, accurate, sensitive, and linear over a wide analytical range, free from significant interferences, and suitable for use in the clinical laboratory.
-
We observed a significant CSF Aβ42 /Aβ40 × p-tau interaction on cortical neurite density index (NDI), but not orientation dispersion index or cortical thickness.
-
This mass spectrometry-based plasma biomarker test: has strong diagnostic performance; can accurately distinguish brain amyloid positive from amyloid negative individuals; may aid in the diagnostic evaluation process for Alzheimer's disease; and may enhance the efficiency of enrolling participants into Alzheimer's disease drug trials.
-
There is an urgent need to establish blood biomarkers for Alzheimer's disease (AD).
-
Among diagnostic groups, highest plasma Nfl and t-tau concentrations were detected in CJD (fold changes of 38 and 18, respectively, compared to HC).
-
In non-demented individuals along the AD continuum, p-tau drives cognitive dysfunction.
-
This review provides a concise overview of recent advances in cerebrospinal fluid (CSF) and blood-based biomarkers of Alzheimer's disease lesions.
-
Plasma P-tau181/Aβ42 ratio may be a noninvasive means of identifying AD with elevated brain amyloid in populations with concomitant CeVD.
-
Plasma NfL indicates neurodegeneration while plasma p-tau181 levels can serve as a biomarker of cerebral AD pathology and cognitive decline.
-
There were significant associations (p < 0.05) between the NPI variables (total score, Affective factor) and entorhinal and precuneus tau across all participants.
-
Higher CSF NfL was associated with decreasing microstructural integrity and WMH.
-
Mild cognitive impairment (MCI) associated with physical frailty gave rise to the new concept of cognitive frailty.
-
43/100
Four fluid-based biomarkers have been developed into diagnostic tests for Alzheimer's disease (AD) pathology: the ratio of 42 to 40 amino acid-long amyloid β, a marker of plaque pathology; total-tau and phosphorylated tau, markers of AD-related changes in tau metabolism and secretion; and neurofilament light, a marker of neurodegeneration.
-
Systemic comorbidity precipitates the risk for dementia.
-
P-tau181 detected AD at MCI and dementia stages and was strongly associated with cognitive decline and gray matter loss.
-
Although Alzheimer's disease (AD) is the most common neurodegenerative disease, there are still no drugs available to treat or prevent AD effectively.
-
Glial fibrillary acidic protein (GFAP), an astrocytic cytoskeletal protein, can be measured in blood samples, and has been associated with Alzheimer's disease (AD).
-
Currently available assays for sampling plasma ATN biomarkers appear to differentiate between AD patients and controls.
-
After 20 years of follow-up, 123 patients (95%) were deceased.
-
A timely diagnosis of frontotemporal degeneration (FTD) is frequently challenging due to the heterogeneous symptomatology and poor phenotype-pathological correlation.
-
Compared to cognitively normal subjects, AD-spectrum patients (i.e., EMCI, LMCI, and AD) showed a reversing trend toward an association between CSF pathological markers and the abnormal SRN occurring during the progression of AD.
-
CU and Obj‐SCD has lower baseline p‐tau181 than MCI and did not differ from one another.
-
In total, 740 proteins were identified of which, 25 differentially-expressed proteins in AD came from comparisons within a single racial and ethnic background group.
-
A panel of structure- and concentration-based plasma amyloid biomarkers may predict conversion to clinical MCI and dementia due to AD in cognitively unimpaired subjects.
-
The NTK contains promising markers that improve the pathophysiological characterization of AD.
-
Mass spectrometry (MS)-based protein identification via MALDI ToF/ToF showed that fibrinogen-β-chain (spot 64) and fibrinogen-γ-chain (spot 91) with differential expression ratio >1.5 were significantly upregulated (p < 0.05) in AD patients when compared to non-AD individuals.
-
Plasma phospho-tau217 correlated with plasma phospho-tau181, CSF phospho-tau217 (rs = 0.68, P < 0.001), and negatively with CSF β-amyloid42/40 (rs = -0.52, P = 0.001).
-
N-p-tau217 and N-p-tau181 could improve diagnostic accuracy in prodromal-AD and clinical trial recruitment as both identify Aβ pathophysiology and differentiate early MCI-AD better than Mid-p-tau181.
-
The CSF α-synuclein levels correlated with AD-specific biomarkers, CSF total tau and phosphorylated tau levels, in 651 Chinese Han participants (training set).
-
Neurofilament light chain (NfL) is a novel biomarker of neurodegenerative diseases.
-
39/100
CSF Aβ42, total tau (t-tau) and phosphorylated tau (p-tau) significantly differed across the three groups.
-
A plethora of dynamic pathophysiological mechanisms underpins highly heterogeneous phenotypes in the field of dementia, particularly in Alzheimer's disease (AD).
-
Highly sensitive and specific plasma biomarkers for Alzheimer's disease (AD) have the potential to improve diagnostic accuracy in the clinic and facilitate research studies including enrollment in prevention and treatment trials.
-
These results indicate that an increase in the baseline level of amyloid peptides, which are associated with an increase in p-tau (181), may be a biological characteristic and possibly a risk factor for AD.
-
Plasma NT1 tau was specifically elevated in AD, but not in non-AD dementia compared with controls, whereas NfL was increased in both AD and non-AD dementias.
-
54/100
NfL had a stronger association than t-tau with clinical scales; t-tau did not hold additional information to that given by NfL (P > 0.05 at all time points).
-
The combination BBBM with MMSE is projected to increase the efficiency and value of the triage process for DMT eligibility.
-
In the total sample, T-tau and Aβ42/p-tau correlated with the total CAMCOG (P < .01); all biomarkers correlated with memory (P < .001); T-tau correlated with language (P < .01).
-
Cerebrospinal fluid (CSF) neurofilament light (NfL) concentration has reproducibly been shown to reflect neurodegeneration in brain disorders, including Alzheimer's disease (AD).
-
Blood biomarkers have great potential to advance clinical care and accelerate trials in Alzheimer's disease (AD).
-
Multiple biological pathways are altered and could be targeted very early in the Alzheimer's continuum.
-
54/100
CSF irisin correlated positively with BDNF, Aβ42, and MMSE scores, but not with CSF total tau.
-
Neurodegenerative diseases are a growing burden, and there is an urgent need for better biomarkers for diagnosis, prognosis, and treatment efficacy.
From across this tag
10 of the 704 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- Conflicting cerebrospinal fluid biomarkers and progression to dementia due to Alzheimer's disease
- Performance of blood biomarkers in internal jugular vein for Alzheimer's disease pathologies: the Delta Method study
- Combining plasma phospho-tau and accessible measures to evaluate progression to Alzheimer's dementia in mild cognitive impairment patients
- Scalable plasma and digital cognitive markers for diagnosis and prognosis of Alzheimer's disease and related dementias
- Biomarker profile of a Chinese ALS cohort: A comprehensive clinical-biomarkers-imaging analysis
- Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer's disease
- Increased cerebrospinal fluid tau levels in logopenic variant of Alzheimer's disease
- Biological variation estimates of Alzheimer's disease plasma biomarkers in healthy individuals
- Quantification of neurofilament light and glial fibrillary acidic protein in finger-prick blood
- C-terminal neurogranin is increased in cerebrospinal fluid but unchanged in plasma in Alzheimer's disease